ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "cd6b82dc-ece6-486e-9984-01db87780dda"}, "_deposit": {"id": "30970", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "30970"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00030970", "sets": ["2601"]}, "item_9_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2020-11", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "4", "bibliographicPageEnd": "644", "bibliographicPageStart": "631", "bibliographicVolumeNumber": "82", "bibliographic_titles": [{"bibliographic_title": "Nagoya Journal of Medical Science"}]}]}, "item_9_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Solitary fibrous tumor/hemangiopericytoma (SFT/HPC) is a rare tumor derived from mesenchymal tissue. Although standard chemotherapy for SHT/HPC has not been established, temozolomide plus bevacizumab (TMZ+Bev) therapy for SFT/HPC has been reported. The effectiveness and safety of TMZ+Bev (temo-zolomide 150 mg/m2 orally on days 1–7 and days 15–21 and bevacizumab 5 mg/kg intravenously on day 8 and day 22 on a 28-day cycle), which was administered from December 2013 until April 2019 to four patients with SFT/HPC, were retrospectively analyzed. Four patients with SFT/HPC received TMZ+Bev. The age of the patients ranged from 41 to 75 years. Two were male, and the primary tumor sites were the meninges in three patients and the pleura in one. One achieved partial response; the others, stable disease (SD). The progression-free survival time ranged from 9.4 to 29.6 months according to RECIST v1.1. One patient died 59 months after using TMZ+Bev, and the others survived for 17 to 64 months. All patients experienced Grade 3 or higher lymphopenia, and three had Grade 3 or higher leukopenia and neutropenia. One patient subsequently received doxorubicin; another, pazopanib. TMZ+Bev therapy for SFT/HPC is safe and effective for maintaining long-term SD.", "subitem_description_type": "Abstract"}]}, "item_9_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.18999/nagjms.82.4.631", "subitem_identifier_reg_type": "JaLC"}]}, "item_9_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Nagoya University Graduate School of Medicine, School of Medicine"}]}, "item_9_relation_43": {"attribute_name": "異版である", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/824.html ", "subitem_relation_type_select": "URI"}}]}, "item_9_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_9_source_id_61": {"attribute_name": "ISSN(Online)", "attribute_value_mlt": [{"subitem_source_identifier": "2186-3326", "subitem_source_identifier_type": "ISSN"}]}, "item_9_source_id_7": {"attribute_name": "ISSN(print)", "attribute_value_mlt": [{"subitem_source_identifier": "0027-7622", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Maeda, Osamu"}], "nameIdentifiers": [{"nameIdentifier": "102387", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ohka, Fumiharu"}], "nameIdentifiers": [{"nameIdentifier": "102388", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Maesawa, Satoshi"}], "nameIdentifiers": [{"nameIdentifier": "102389", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsuoka, Ayumu"}], "nameIdentifiers": [{"nameIdentifier": "102390", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shimokata, Tomoya"}], "nameIdentifiers": [{"nameIdentifier": "102391", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mitsuma, Ayako"}], "nameIdentifiers": [{"nameIdentifier": "102392", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Urakawa, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "102393", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakamura, Shota"}], "nameIdentifiers": [{"nameIdentifier": "102394", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shimoyama, Yoshie"}], "nameIdentifiers": [{"nameIdentifier": "102395", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakaguro, Masato"}], "nameIdentifiers": [{"nameIdentifier": "102396", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Wakabayashi, Toshihiko"}], "nameIdentifiers": [{"nameIdentifier": "102397", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ando, Yuichi"}], "nameIdentifiers": [{"nameIdentifier": "102398", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-11-26"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "04_Maeda-1.pdf", "filesize": [{"value": "54.7 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 54700000.0, "url": {"label": "04_Maeda-1.pdf", "url": "https://nagoya.repo.nii.ac.jp/record/30970/files/04_Maeda-1.pdf"}, "version_id": "18ce190d-a38d-4e05-89e5-eb852edbcb73"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "solitary fibrous tumor", "subitem_subject_scheme": "Other"}, {"subitem_subject": "hemangiopericytoma", "subitem_subject_scheme": "Other"}, {"subitem_subject": "temozolomide", "subitem_subject_scheme": "Other"}, {"subitem_subject": "bevacizumab", "subitem_subject_scheme": "Other"}, {"subitem_subject": "chemotherapy", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Solitary fibrous tumor/hemangiopericytoma treated with temozolomide plus bevacizumab: a report of four cases and literature review", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Solitary fibrous tumor/hemangiopericytoma treated with temozolomide plus bevacizumab: a report of four cases and literature review"}]}, "item_type_id": "9", "owner": "1", "path": ["2601"], "permalink_uri": "https://doi.org/10.18999/nagjms.82.4.631", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-11-26"}, "publish_date": "2020-11-26", "publish_status": "0", "recid": "30970", "relation": {}, "relation_version_is_last": true, "title": ["Solitary fibrous tumor/hemangiopericytoma treated with temozolomide plus bevacizumab: a report of four cases and literature review"], "weko_shared_id": 3}
  1. C100 医学部/医学系研究科
  2. C100b 紀要
  3. Nagoya journal of medical science
  4. 82(4)

Solitary fibrous tumor/hemangiopericytoma treated with temozolomide plus bevacizumab: a report of four cases and literature review

https://doi.org/10.18999/nagjms.82.4.631
https://doi.org/10.18999/nagjms.82.4.631
235cbd4a-248b-46f0-a3d7-385073e5f7c9
名前 / ファイル ライセンス アクション
04_Maeda-1.pdf 04_Maeda-1.pdf (54.7 MB)
Item type 紀要論文 / Departmental Bulletin Paper(1)
公開日 2020-11-26
タイトル
タイトル Solitary fibrous tumor/hemangiopericytoma treated with temozolomide plus bevacizumab: a report of four cases and literature review
著者 Maeda, Osamu

× Maeda, Osamu

WEKO 102387

Maeda, Osamu

Search repository
Ohka, Fumiharu

× Ohka, Fumiharu

WEKO 102388

Ohka, Fumiharu

Search repository
Maesawa, Satoshi

× Maesawa, Satoshi

WEKO 102389

Maesawa, Satoshi

Search repository
Matsuoka, Ayumu

× Matsuoka, Ayumu

WEKO 102390

Matsuoka, Ayumu

Search repository
Shimokata, Tomoya

× Shimokata, Tomoya

WEKO 102391

Shimokata, Tomoya

Search repository
Mitsuma, Ayako

× Mitsuma, Ayako

WEKO 102392

Mitsuma, Ayako

Search repository
Urakawa, Hiroshi

× Urakawa, Hiroshi

WEKO 102393

Urakawa, Hiroshi

Search repository
Nakamura, Shota

× Nakamura, Shota

WEKO 102394

Nakamura, Shota

Search repository
Shimoyama, Yoshie

× Shimoyama, Yoshie

WEKO 102395

Shimoyama, Yoshie

Search repository
Nakaguro, Masato

× Nakaguro, Masato

WEKO 102396

Nakaguro, Masato

Search repository
Wakabayashi, Toshihiko

× Wakabayashi, Toshihiko

WEKO 102397

Wakabayashi, Toshihiko

Search repository
Ando, Yuichi

× Ando, Yuichi

WEKO 102398

Ando, Yuichi

Search repository
キーワード
主題Scheme Other
主題 solitary fibrous tumor
キーワード
主題Scheme Other
主題 hemangiopericytoma
キーワード
主題Scheme Other
主題 temozolomide
キーワード
主題Scheme Other
主題 bevacizumab
キーワード
主題Scheme Other
主題 chemotherapy
抄録
内容記述 Solitary fibrous tumor/hemangiopericytoma (SFT/HPC) is a rare tumor derived from mesenchymal tissue. Although standard chemotherapy for SHT/HPC has not been established, temozolomide plus bevacizumab (TMZ+Bev) therapy for SFT/HPC has been reported. The effectiveness and safety of TMZ+Bev (temo-zolomide 150 mg/m2 orally on days 1–7 and days 15–21 and bevacizumab 5 mg/kg intravenously on day 8 and day 22 on a 28-day cycle), which was administered from December 2013 until April 2019 to four patients with SFT/HPC, were retrospectively analyzed. Four patients with SFT/HPC received TMZ+Bev. The age of the patients ranged from 41 to 75 years. Two were male, and the primary tumor sites were the meninges in three patients and the pleura in one. One achieved partial response; the others, stable disease (SD). The progression-free survival time ranged from 9.4 to 29.6 months according to RECIST v1.1. One patient died 59 months after using TMZ+Bev, and the others survived for 17 to 64 months. All patients experienced Grade 3 or higher lymphopenia, and three had Grade 3 or higher leukopenia and neutropenia. One patient subsequently received doxorubicin; another, pazopanib. TMZ+Bev therapy for SFT/HPC is safe and effective for maintaining long-term SD.
内容記述タイプ Abstract
出版者
出版者 Nagoya University Graduate School of Medicine, School of Medicine
言語
言語 eng
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
ID登録
ID登録 10.18999/nagjms.82.4.631
ID登録タイプ JaLC
関連情報
関連タイプ isVersionOf
識別子タイプ URI
関連識別子 http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/824.html
ISSN(print)
収録物識別子タイプ ISSN
収録物識別子 0027-7622
ISSN(Online)
収録物識別子タイプ ISSN
収録物識別子 2186-3326
書誌情報 Nagoya Journal of Medical Science

巻 82, 号 4, p. 631-644, 発行日 2020-11
著者版フラグ
値 publisher
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 08:38:20.312066
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3